A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs S 033188 (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms CAPSTONE 1
- Sponsors Shionogi
- 24 Jul 2017 According to a Shionogi media release, based on the results from CAPSTONE-1, Shionogi plans to submit a New Drug Application (NDA) to the PMDA in Japan later this year.
- 24 Jul 2017 Primary endpoint has been met. (Time to alleviation of symptoms), according to a Shionogi media release.
- 24 Jul 2017 Top-line results published in a Shionogi media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History